The University of Chicago Header Logo

Connection

Yusuke Nakamura to Neoplasms

Back to Details
This is a "connection" page, showing publications Yusuke Nakamura has written about Neoplasms.
Yusuke Nakamura
Connection Strength
4.696
Neoplasms
  1. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
    View in: PubMed
    Score: 0.286
  2. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy. J Transl Med. 2022 05 23; 20(1):241.
    View in: PubMed
    Score: 0.251
  3. Integrative cancer genomics in the era of precision cancer medicine. J Hum Genet. 2021 09; 66(9):843.
    View in: PubMed
    Score: 0.238
  4. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.
    View in: PubMed
    Score: 0.237
  5. Immunogenomics in personalized cancer treatments. J Hum Genet. 2021 Sep; 66(9):901-907.
    View in: PubMed
    Score: 0.236
  6. The road map of cancer precision medicine with the innovation of advanced cancer detection technology and personalized immunotherapy. Jpn J Clin Oncol. 2019 Jul 01; 49(7):596-603.
    View in: PubMed
    Score: 0.205
  7. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar; 109(3):542-549.
    View in: PubMed
    Score: 0.187
  8. Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy. Trends Pharmacol Sci. 2017 01; 38(1):15-24.
    View in: PubMed
    Score: 0.171
  9. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Oncotarget. 2016 Apr 05; 7(14):18171-82.
    View in: PubMed
    Score: 0.164
  10. Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy. Cancer Sci. 2016 Apr; 107(4):377-84.
    View in: PubMed
    Score: 0.162
  11. Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Sci. 2016 Feb; 107(2):107-15.
    View in: PubMed
    Score: 0.162
  12. Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug; 104(8):1074-82.
    View in: PubMed
    Score: 0.135
  13. Cancer vaccines. Clin Adv Hematol Oncol. 2011 Oct; 9(10):778-9.
    View in: PubMed
    Score: 0.120
  14. The BioBank Japan Project. Clin Adv Hematol Oncol. 2007 Sep; 5(9):696-7.
    View in: PubMed
    Score: 0.090
  15. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005 Oct; 37(10):1104-7.
    View in: PubMed
    Score: 0.079
  16. Automated and Decentralized Genomic Profiling of Plasma Cell-Free DNA for Identification of Targetable and Resistance Alterations in Advanced Solid Tumors. Clin Chem. 2025 Jun 03; 71(6):700-712.
    View in: PubMed
    Score: 0.077
  17. Bispecific antibody targeting shared indel-derived neoantigen of APC. Front Immunol. 2025; 16:1574958.
    View in: PubMed
    Score: 0.077
  18. Identification of shared neoantigens derived from frameshift mutations in the APC gene. Front Immunol. 2025; 16:1574955.
    View in: PubMed
    Score: 0.077
  19. Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
    View in: PubMed
    Score: 0.077
  20. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004 Aug; 6(8):731-40.
    View in: PubMed
    Score: 0.073
  21. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004 Jan; 95(1):7-11.
    View in: PubMed
    Score: 0.070
  22. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine. Front Immunol. 2023; 14:1223331.
    View in: PubMed
    Score: 0.069
  23. Head-to-head comparison of three chelates reveals DOTAGA promising for 225 Ac labeling of anti-FZD10 antibody OTSA101. Cancer Sci. 2023 Dec; 114(12):4677-4690.
    View in: PubMed
    Score: 0.069
  24. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002 Jan 15; 62(2):518-27.
    View in: PubMed
    Score: 0.061
  25. Clinical implementation and current advancement of blood liquid biopsy in cancer. J Hum Genet. 2021 Sep; 66(9):909-926.
    View in: PubMed
    Score: 0.059
  26. Clinicopathologic significance of protein lysine methyltransferases in cancer. Clin Epigenetics. 2020 10 13; 12(1):146.
    View in: PubMed
    Score: 0.056
  27. Diagnostic utility and pitfalls of intraoperative pulmonary imprint cytology based on final pathological diagnoses. Cytopathology. 2019 01; 30(1):74-81.
    View in: PubMed
    Score: 0.049
  28. A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors. PLoS One. 2018; 13(1):e0187878.
    View in: PubMed
    Score: 0.046
  29. Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study. JAMA Oncol. 2017 May 01; 3(5):636-651.
    View in: PubMed
    Score: 0.044
  30. Statin use and all-cause and cancer mortality: BioBank Japan cohort. J Epidemiol. 2017 Mar; 27(3S):S84-S91.
    View in: PubMed
    Score: 0.043
  31. Survival of macrovascular disease, chronic kidney disease, chronic respiratory disease, cancer and smoking in patients with type 2 diabetes: BioBank Japan cohort. J Epidemiol. 2017 Mar; 27(3S):S98-S106.
    View in: PubMed
    Score: 0.043
  32. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
    View in: PubMed
    Score: 0.041
  33. SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. Oncotarget. 2015 Dec 22; 6(41):43162-71.
    View in: PubMed
    Score: 0.040
  34. Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
    View in: PubMed
    Score: 0.040
  35. PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP. Oncotarget. 2015 Nov 03; 6(34):35173-82.
    View in: PubMed
    Score: 0.040
  36. SUV39H2 methylates and stabilizes LSD1 by inhibiting polyubiquitination in human cancer cells. Oncotarget. 2015 Jul 10; 6(19):16939-50.
    View in: PubMed
    Score: 0.039
  37. The NSD family of protein methyltransferases in human cancer. Epigenomics. 2015 Aug; 7(5):863-74.
    View in: PubMed
    Score: 0.038
  38. Guidance for peptide vaccines for the treatment of cancer. Cancer Sci. 2014 Jul; 105(7):924-31.
    View in: PubMed
    Score: 0.036
  39. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor. Clin Cancer Res. 2013 Aug 15; 19(16):4508-20.
    View in: PubMed
    Score: 0.034
  40. MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells. Cell Cycle. 2013 Jun 01; 12(11):1655-6.
    View in: PubMed
    Score: 0.034
  41. Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.
    View in: PubMed
    Score: 0.033
  42. The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes Cancer. 2013 Feb; 52(2):126-39.
    View in: PubMed
    Score: 0.032
  43. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia. 2011 Oct; 13(10):887-98.
    View in: PubMed
    Score: 0.030
  44. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet Genomics. 2011 Sep; 21(9):552-8.
    View in: PubMed
    Score: 0.030
  45. Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. Neoplasia. 2011 Aug; 13(8):676-84.
    View in: PubMed
    Score: 0.030
  46. Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Mol Cancer. 2011 May 28; 10:65.
    View in: PubMed
    Score: 0.029
  47. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011 Jul; 102(7):1298-305.
    View in: PubMed
    Score: 0.029
  48. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
    View in: PubMed
    Score: 0.029
  49. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2011 Feb 01; 128(3):574-86.
    View in: PubMed
    Score: 0.029
  50. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer. 2011 Feb 01; 128(3):562-73.
    View in: PubMed
    Score: 0.029
  51. Demethylation of RB regulator MYPT1 by histone demethylase LSD1 promotes cell cycle progression in cancer cells. Cancer Res. 2011 Feb 01; 71(3):655-60.
    View in: PubMed
    Score: 0.028
  52. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer. 2010 Sep 01; 127(6):1393-403.
    View in: PubMed
    Score: 0.028
  53. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res. 2010 Jul 01; 70(13):5326-36.
    View in: PubMed
    Score: 0.027
  54. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010 May 01; 126(9):2153-63.
    View in: PubMed
    Score: 0.027
  55. International network of cancer genome projects. Nature. 2010 Apr 15; 464(7291):993-8.
    View in: PubMed
    Score: 0.027
  56. Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 2009 Oct; 54(10):572-80.
    View in: PubMed
    Score: 0.026
  57. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med. 2009 Jul; 23(5):479-85.
    View in: PubMed
    Score: 0.025
  58. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007 Sep 15; 67(18):8544-53.
    View in: PubMed
    Score: 0.023
  59. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 2007 Sep; 6(9):3475-83.
    View in: PubMed
    Score: 0.023
  60. Serial analysis of gene expression in progressing and regressing mouse tumors implicates the involvement of RANTES and TARC in antitumor immune responses. Mol Ther. 2006 Oct; 14(4):599-606.
    View in: PubMed
    Score: 0.021
  61. Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene. 2005 Jul 28; 24(32):5131-6.
    View in: PubMed
    Score: 0.020
  62. Adenovirus-mediated p53AIP1 gene transfer as a new strategy for treatment of p53-resistant tumors. Cancer Sci. 2004 Jan; 95(1):91-7.
    View in: PubMed
    Score: 0.018
  63. Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. Cancer Sci. 2003 Dec; 94(12):1074-82.
    View in: PubMed
    Score: 0.017
  64. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Feb 15; 62(4):1139-47.
    View in: PubMed
    Score: 0.015
  65. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1. Oncotarget. 2016 Nov 15; 7(46):75023-75037.
    View in: PubMed
    Score: 0.011
  66. Identification of p53-46F as a super p53 with an enhanced ability to induce p53-dependent apoptosis. Cancer Sci. 2006 Jul; 97(7):633-41.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.